<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340079</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1049</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091049</ELocationID><Abstract><AbstractText>Inducing T lymphocyte (T-cell) activation and proliferation with specificity against a pathogen is crucial in vaccine formulation. Assessing vaccine candidates' ability to induce T-cell proliferation helps optimize formulation for its safety, immunogenicity, and efficacy. Our in-house vaccine candidates use microparticles (MPs) and nanoparticles (NPs) to enhance antigen stability and target delivery to antigen-presenting cells (APCs), providing improved immunogenicity. Typically, vaccine formulations are screened for safety and immunostimulatory effects using in vitro methods, but extensive animal testing is often required to assess immunogenic responses. We identified the need for a rapid, intermediate screening process to select promising candidates before advancing to expensive and time-consuming in vivo evaluations. In this study, an in vitro overlay assay system was demonstrated as an effective high-throughput preclinical testing method to evaluate the immunogenic properties of early-stage vaccine formulations. The overlay assay's effectiveness in testing particulate vaccine candidates for immunogenic responses has been evaluated by optimizing the carboxyfluorescein succinimidyl ester (CFSE) T-cell proliferation assay. DCs were overlaid with T-cells, allowing vaccine-stimulated DCs to present antigens to CFSE-stained T-cells. T-cell proliferation was quantified using flow cytometry on days 0, 1, 2, 4, and 6 upon successful antigen presentation. The assay was tested with nanoparticulate vaccine formulations targeting <i>Neisseria gonorrhoeae</i> (CDC F62, FA19, FA1090), measles, H1N1 flu prototype, canine coronavirus, and Zika, with adjuvants including Alhydrogel<sup>®</sup> (Alum) and AddaVax™. The assay revealed robust T-cell proliferation in the vaccine treatment groups, with variations between bacterial and viral vaccine candidates. A dose-dependent study indicated immune stimulation varied with antigen dose. These findings highlight the assay's potential to differentiate and quantify effective antigen presentation, providing valuable insights for developing and optimizing vaccine formulations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasupuleti</LastName><ForeName>Dedeepya</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0007-4780-9658</Identifier><AffiliationInfo><Affiliation>Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagwe</LastName><ForeName>Priyal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7151-5018</Identifier><AffiliationInfo><Affiliation>Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Amarae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uddin</LastName><ForeName>Mohammad N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Souza</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zughaier</LastName><ForeName>Susu M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-7487-8770</Identifier><AffiliationInfo><Affiliation>College of Medicine, QU Health, Qatar University, Doha P.O. Box 2731, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R15AI133473-01A1</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CFSE</Keyword><Keyword MajorTopicYN="N">T-cell proliferation</Keyword><Keyword MajorTopicYN="N">antigen presentation</Keyword><Keyword MajorTopicYN="N">antigen-presenting cell</Keyword><Keyword MajorTopicYN="N">cell-to-cell contact</Keyword><Keyword MajorTopicYN="N">dendritic cell</Keyword><Keyword MajorTopicYN="N">in vitro vaccine screening</Keyword><Keyword MajorTopicYN="N">overlay assay</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of this study, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340079</ArticleId><ArticleId IdType="pmc">PMC11435973</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091049</ArticleId><ArticleId IdType="pii">vaccines12091049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turner S.J., Bennett T.J., La Gruta N.L. CD8 + T-Cell Memory: The Why, the When, and the How. Cold Spring Harb. Perspect. Biol. 2021;13:a038661. doi: 10.1101/cshperspect.a038661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a038661</ArticleId><ArticleId IdType="pmc">PMC8091951</ArticleId><ArticleId IdType="pubmed">33648987</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh C.-H., Lee S., Kwak M., Kim B.-S., Chung Y. CD8 T-Cell Subsets: Heterogeneity, Functions, and Therapeutic Potential. Exp. Mol. Med. 2023;55:2287–2299. doi: 10.1038/s12276-023-01105-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-01105-x</ArticleId><ArticleId IdType="pmc">PMC10689838</ArticleId><ArticleId IdType="pubmed">37907738</ArticleId></ArticleIdList></Reference><Reference><Citation>Soerens A.G., Künzli M., Quarnstrom C.F., Scott M.C., Swanson L., Locquiao J., Ghoneim H.E., Zehn D., Youngblood B., Vezys V., et al. Functional T Cells Are Capable of Supernumerary Cell Division and Longevity. Nature. 2023;614:762–766. doi: 10.1038/s41586-022-05626-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05626-9</ArticleId><ArticleId IdType="pubmed">36653453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ura T., Takeuchi M., Kawagoe T., Mizuki N., Okuda K., Shimada M. Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines. 2022;10:1367. doi: 10.3390/vaccines10081367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081367</ArticleId><ArticleId IdType="pmc">PMC9413345</ArticleId><ArticleId IdType="pubmed">36016254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M., Rabaan A.A., Fawarah M.M.A., Almuthree S.A., Alsubki R.A., Alfaraj A.H., Mashraqi M.M., Alshamrani S.A., Abduljabbar W.A., Alwashmi A.S.S., et al. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines. 2023;11:101. doi: 10.3390/vaccines11010101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010101</ArticleId><ArticleId IdType="pmc">PMC9861463</ArticleId><ArticleId IdType="pubmed">36679947</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury N., Kundu A. Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus. Diseases. 2023;11:177. doi: 10.3390/diseases11040177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases11040177</ArticleId><ArticleId IdType="pmc">PMC10742622</ArticleId><ArticleId IdType="pubmed">38131983</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes Chaves L., Dourado D., Prunache I.-B., Manuelle Marques Da Silva P., Tacyana Dos Santos Lucena G., Cardoso De Souza Z., Muniz Mendes Freire De Moura P., Nunes Bordallo H., Rocha Formiga F., De Souza Rebouças J. Nanocarriers of Antigen Proteins for Vaccine Delivery. Int. J. Pharm. 2024;659:124162. doi: 10.1016/j.ijpharm.2024.124162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2024.124162</ArticleId><ArticleId IdType="pubmed">38663646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsen M.O., Zha L., Cabral-Miranda G., Bachmann M.F. Major Findings and Recent Advances in Virus–like Particle (VLP)-Based Vaccines. Semin. Immunol. 2017;34:123–132. doi: 10.1016/j.smim.2017.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2017.08.014</ArticleId><ArticleId IdType="pubmed">28887001</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz Gomes K., Vijayanand S., Bagwe P., Menon I., Kale A., Patil S., Kang S.-M., Uddin M.N., D’Souza M.J. Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles. Int. J. Mol. Sci. 2023;24:10612. doi: 10.3390/ijms241310612.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310612</ArticleId><ArticleId IdType="pmc">PMC10341628</ArticleId><ArticleId IdType="pubmed">37445784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagwe P., Bajaj L., Menon I., Braz Gomes K., Kale A., Patil S., Vijayanand S., Gala R., D’Souza M.J., Zughaier S.M. Gonococcal Microparticle Vaccine in Dissolving Microneedles Induced Immunity and Enhanced Bacterial Clearance in Infected Mice. Int. J. Pharm. 2023;642:123182. doi: 10.1016/j.ijpharm.2023.123182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2023.123182</ArticleId><ArticleId IdType="pmc">PMC10529368</ArticleId><ArticleId IdType="pubmed">37369287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman R.U., Mulla N.S., Braz Gomes K., D’Souza C., Murnane K.S., D’Souza M.J. Nanoparticle Formulations That Allow for Sustained Delivery and Brain Targeting of the Neuropeptide Oxytocin. Int. J. Pharm. 2018;548:698–706. doi: 10.1016/j.ijpharm.2018.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.07.043</ArticleId><ArticleId IdType="pmc">PMC6092754</ArticleId><ArticleId IdType="pubmed">30031864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kale A., Joshi D., Menon I., Bagwe P., Patil S., Vijayanand S., Braz Gomes K., D’Souza M. Novel Microparticulate Zika Vaccine Induces a Significant Immune Response in a Preclinical Murine Model after Intramuscular Administration. Int. J. Pharm. 2022;624:121975. doi: 10.1016/j.ijpharm.2022.121975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2022.121975</ArticleId><ArticleId IdType="pubmed">35787459</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Masuda K., Groso C., Hassan R., Zhou Z., Broderick K., Tsuji M., Tison C. Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines. Vaccines. 2024;12:339. doi: 10.3390/vaccines12030339.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030339</ArticleId><ArticleId IdType="pmc">PMC10975406</ArticleId><ArticleId IdType="pubmed">38543973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham A.L., Garçon N., Leo O., Friedland L.R., Strugnell R., Laupèze B., Doherty M., Stern P. Vaccine Development: From Concept to Early Clinical Testing. Vaccine. 2016;34:6655–6664. doi: 10.1016/j.vaccine.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.016</ArticleId><ArticleId IdType="pubmed">27769596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal G., Särnefält A., Kumar A. Considerations for Bioanalytical Characterization and Batch Release of COVID-19 Vaccines. npj Vaccines. 2021;6:53. doi: 10.1038/s41541-021-00317-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00317-4</ArticleId><ArticleId IdType="pmc">PMC8044082</ArticleId><ArticleId IdType="pubmed">33850138</ArticleId></ArticleIdList></Reference><Reference><Citation>Haber P., Sejvar J., Mikaeloff Y., DeStefano F. Vaccines and Guillain-Barré Syndrome. Drug Saf. 2009;32:309–323. doi: 10.2165/00002018-200932040-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200932040-00005</ArticleId><ArticleId IdType="pubmed">19388722</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao S.-C., Wang C.-H., Chang K.-C., Hung M.-J., Chen H.-Y., Liao S.-C. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg. Infect. Dis. 2021;27:3175–3178. doi: 10.3201/eid2712.211634.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2712.211634</ArticleId><ArticleId IdType="pmc">PMC8632191</ArticleId><ArticleId IdType="pubmed">34648420</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiglione J.I., Crespo J.M., Bendersky M., Silveira F.O., Lecchini L., Luis M.B., Zambrano F.C., Cotti N., Simison C.J., Aguirre F., et al. Guillain-Barré Syndrome and COVID-19 Vaccine: A Multicenter Retrospective Study of 46 Cases. J. Clin. Neuromuscul. Dis. 2023;25:1–10. doi: 10.1097/CND.0000000000000437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000437</ArticleId><ArticleId IdType="pubmed">37611264</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Neurological Adverse Reactions to SARS-CoV-2 Vaccines. Clin. Psychopharmacol. Neurosci. 2023;21:222–239. doi: 10.9758/cpn.2023.21.2.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2023.21.2.222</ArticleId><ArticleId IdType="pmc">PMC10157009</ArticleId><ArticleId IdType="pubmed">37119215</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S., Kim D.H., Shin J.U. In Vitro Models Mimicking Immune Response in the Skin. Yonsei Med. J. 2021;62:969. doi: 10.3349/ymj.2021.62.11.969.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2021.62.11.969</ArticleId><ArticleId IdType="pmc">PMC8542468</ArticleId><ArticleId IdType="pubmed">34672130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammel J.H., Cook S.R., Belanger M.C., Munson J.M., Pompano R.R. Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues. Annu. Rev. Biomed. Eng. 2021;23:461–491. doi: 10.1146/annurev-bioeng-082420-124920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-bioeng-082420-124920</ArticleId><ArticleId IdType="pmc">PMC8277680</ArticleId><ArticleId IdType="pubmed">33872520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya S., Calar K., de la Puente P. Mimicking Tumor Hypoxia and Tumor-Immune Interactions Employing Three-Dimensional in Vitro Models. J. Exp. Clin. Cancer Res. 2020;39:75. doi: 10.1186/s13046-020-01583-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-020-01583-1</ArticleId><ArticleId IdType="pmc">PMC7195738</ArticleId><ArticleId IdType="pubmed">32357910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gala R., Zaman R., D’Souza M., Zughaier S. Novel Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticles as Vaccine Formulation in Microneedle-Based Transdermal Immunization. Vaccines. 2018;6:60. doi: 10.3390/vaccines6030060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines6030060</ArticleId><ArticleId IdType="pmc">PMC6161099</ArticleId><ArticleId IdType="pubmed">30181504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagwe P., Bajaj L., Gala R.P., D’Souza M.J., Zughaier S.M. Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria Gonorrhoeae Microparticle Vaccine Formulation. Vaccines. 2022;10:983. doi: 10.3390/vaccines10070983.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10070983</ArticleId><ArticleId IdType="pmc">PMC9320116</ArticleId><ArticleId IdType="pubmed">35891147</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi D., Gala R.P., Uddin M.N., D’Souza M.J. Novel Ablative Laser Mediated Transdermal Immunization for Microparticulate Measles Vaccine. Int. J. Pharm. 2021;606:120882. doi: 10.1016/j.ijpharm.2021.120882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120882</ArticleId><ArticleId IdType="pubmed">34298102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gala R.P., Popescu C., Knipp G.T., McCain R.R., Ubale R.V., Addo R., Bhowmik T., Kulczar C.D., D’Souza M.J. Physicochemical and Preclinical Evaluation of a Novel Buccal Measles Vaccine. AAPS PharmSciTech. 2017;18:283–292. doi: 10.1208/s12249-016-0566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-016-0566-3</ArticleId><ArticleId IdType="pubmed">27357420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubale R.V., D’souza M.J., Infield D.T., McCarty N.A., Zughaier S.M. Formulation of Meningococcal Capsular Polysaccharide Vaccine-Loaded Microparticles with Robust Innate Immune Recognition. J. Microencapsul. 2013;30:28–41. doi: 10.3109/02652048.2012.692402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02652048.2012.692402</ArticleId><ArticleId IdType="pubmed">22657751</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayanand S., Patil S., Joshi D., Menon I., Braz Gomes K., Kale A., Bagwe P., Yacoub S., Uddin M.N., D’Souza M.J. Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus. Vaccines. 2022;10:1491. doi: 10.3390/vaccines10091491.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091491</ArticleId><ArticleId IdType="pmc">PMC9503342</ArticleId><ArticleId IdType="pubmed">36146568</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker E., Van Niekerk S., Hanning K., Kelton W., Hicks J. Mechanisms of Host Manipulation by Neisseria Gonorrhoeae. Front. Microbiol. 2023;14:1119834. doi: 10.3389/fmicb.2023.1119834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1119834</ArticleId><ArticleId IdType="pmc">PMC9935845</ArticleId><ArticleId IdType="pubmed">36819065</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerse A.E., Bash M.C., Russell M.W. Vaccines against Gonorrhea: Current Status and Future Challenges. Vaccine. 2014;32:1579–1587. doi: 10.1016/j.vaccine.2013.08.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.08.067</ArticleId><ArticleId IdType="pmc">PMC4682887</ArticleId><ArticleId IdType="pubmed">24016806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubale R.V., Gala R.P., Zughaier S.M., D’Souza M.J. Induction of Death Receptor CD95 and Co-Stimulatory Molecules CD80 and CD86 by Meningococcal Capsular Polysaccharide-Loaded Vaccine Nanoparticles. AAPS J. 2014;16:986–993. doi: 10.1208/s12248-014-9635-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-014-9635-2</ArticleId><ArticleId IdType="pmc">PMC4147039</ArticleId><ArticleId IdType="pubmed">24981893</ArticleId></ArticleIdList></Reference><Reference><Citation>Verch T., Trausch J.J., Shank-Retzlaff M. Principles of Vaccine Potency Assays. Bioanalysis. 2018;10:163–180. doi: 10.4155/bio-2017-0176.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2017-0176</ArticleId><ArticleId IdType="pubmed">29333863</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauner A., Agrawal P., Salvatico J., Tapia T., Dhir V., Shaik S.F., Drake D.R., Byers A.M. The in Vitro MIMIC® Platform Reflects Age-Associated Changes in Immunological Responses after Influenza Vaccination. Vaccine. 2017;35:5487–5494. doi: 10.1016/j.vaccine.2017.03.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.099</ArticleId><ArticleId IdType="pubmed">28413134</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffman R.L., Sher A., Seder R.A. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity. 2010;33:492–503. doi: 10.1016/j.immuni.2010.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.002</ArticleId><ArticleId IdType="pmc">PMC3420356</ArticleId><ArticleId IdType="pubmed">21029960</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N., Davis Z., Hofmann C., Vlasak J., Loughney J.W., DePhillips P., Mukherjee M. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines. Vaccines. 2023;11:1224. doi: 10.3390/vaccines11071224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071224</ArticleId><ArticleId IdType="pmc">PMC10383996</ArticleId><ArticleId IdType="pubmed">37515040</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S.A. Vaccines: Past, Present and Future. Nat. Med. 2005;11:S5–S11. doi: 10.1038/nm1209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1209</ArticleId><ArticleId IdType="pmc">PMC7095920</ArticleId><ArticleId IdType="pubmed">15812490</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutzik P.O., Irish J.M., Nolan G.P., Perez O.D. Analysis of Protein Phosphorylation and Cellular Signaling Events by Flow Cytometry: Techniques and Clinical Applications. Clin. Immunol. 2004;110:206–221. doi: 10.1016/j.clim.2003.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2003.11.009</ArticleId><ArticleId IdType="pubmed">15047199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendall S.C., Simonds E.F., Qiu P., Amir E.D., Krutzik P.O., Finck R., Bruggner R.V., Melamed R., Trejo A., Ornatsky O.I., et al. Single-Cell Mass Cytometry of Differential Immune and Drug Responses across a Human Hematopoietic Continuum. Science. 2011;332:687–696. doi: 10.1126/science.1198704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1198704</ArticleId><ArticleId IdType="pmc">PMC3273988</ArticleId><ArticleId IdType="pubmed">21551058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P.A., Minervina A.A., Pogorelyy M.V., Turner J.S., Kim W., Kalaidina E., Petersen J., Schmitz A.J., Lei T., Haile A., et al. SARS-CoV-2 mRNA Vaccination Elicits a Robust and Persistent T Follicular Helper Cell Response in Humans. Cell. 2022;185:603–613.e15. doi: 10.1016/j.cell.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar D.G., Yang S.Y.C., Sayad A., Zhao Q., Nguyen L.T., Warner K., Sangster A.G., Nakatsugawa M., Murata K., Wang B.X., et al. Identification of Antigenic Epitopes Recognized by Tumor Infiltrating Lymphocytes in High Grade Serous Ovarian Cancer by Multi-Omics Profiling of the Auto-Antigen Repertoire. Cancer Immunol. Immunother. 2023;72:2375–2392. doi: 10.1007/s00262-023-03413-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-023-03413-7</ArticleId><ArticleId IdType="pmc">PMC10264507</ArticleId><ArticleId IdType="pubmed">36943460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner G., Keller S., Huleatt J., Staack R.F., Wagner L., Azadeh M., Bandukwala A., Cao L., Du X., Salinas G.F., et al. 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2—Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development &amp; Validation; Emerging Technologies; Critical Reagents Deep Characterization. Bioanalysis. 2023;15:861–903. doi: 10.4155/bio-2023-0151.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2023-0151</ArticleId><ArticleId IdType="pubmed">37584363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F., Lin X., Fu B., Xiong Y., Zaky M.Y., Wu H. Functional Studies of HLA and Its Role in SARS-CoV-2: Stimulating T Cell Response and Vaccine Development. Life Sci. 2023;315:121374. doi: 10.1016/j.lfs.2023.121374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.121374</ArticleId><ArticleId IdType="pmc">PMC9815883</ArticleId><ArticleId IdType="pubmed">36621539</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain R.N., Meier-Schellersheim M., Nita-Lazar A., Fraser I.D.C. Systems Biology in Immunology: A Computational Modeling Perspective. Annu. Rev. Immunol. 2011;29:527–585. doi: 10.1146/annurev-immunol-030409-101317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-030409-101317</ArticleId><ArticleId IdType="pmc">PMC3164774</ArticleId><ArticleId IdType="pubmed">21219182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedele G., Trentini F., Schiavoni I., Abrignani S., Antonelli G., Baldo V., Baldovin T., Bandera A., Bonura F., Clerici P., et al. Evaluation of Humoral and Cellular Response to Four Vaccines against COVID-19 in Different Age Groups: A Longitudinal Study. Front. Immunol. 2022;13:1021396. doi: 10.3389/fimmu.2022.1021396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1021396</ArticleId><ArticleId IdType="pmc">PMC9661524</ArticleId><ArticleId IdType="pubmed">36389704</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng S.X., Shaw A.C. Fundamental and Frontier Research of Immune Responses to Influenza Vaccines in Human Aging: From Cross-Sectional and Longitudinal Studies to Clinical Trials and the Geroscience Perspective. Immun. Ageing. 2023;20:69. doi: 10.1186/s12979-023-00392-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-023-00392-2</ArticleId><ArticleId IdType="pmc">PMC10685665</ArticleId><ArticleId IdType="pubmed">38031077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakugawa T., Doi K., Ohteru Y., Kakugawa H., Oishi K., Kakugawa M., Hirano T., Mimura Y., Matsunaga K. Kinetics of COVID-19 mRNA Primary and Booster Vaccine-Associated Neutralizing Activity against SARS-CoV-2 Variants of Concern in Long-Term Care Facility Residents: A Prospective Longitudinal Study in Japan. Immun. Ageing. 2023;20:42. doi: 10.1186/s12979-023-00368-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-023-00368-2</ArticleId><ArticleId IdType="pmc">PMC10433614</ArticleId><ArticleId IdType="pubmed">37592283</ArticleId></ArticleIdList></Reference><Reference><Citation>Karachaliou M., Moncunill G., Espinosa A., Castaño-Vinyals G., Rubio R., Vidal M., Jiménez A., Prados E., Carreras A., Cortés B., et al. SARS-CoV-2 Infection, Vaccination, and Antibody Response Trajectories in Adults: A Cohort Study in Catalonia. BMC Med. 2022;20:347. doi: 10.1186/s12916-022-02547-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02547-2</ArticleId><ArticleId IdType="pmc">PMC9479347</ArticleId><ArticleId IdType="pubmed">36109713</ArticleId></ArticleIdList></Reference><Reference><Citation>Latifi T., Kachooei A., Jalilvand S., Zafarian S., Roohvand F., Shoja Z. Correlates of Immune Protection against Human Rotaviruses: Natural Infection and Vaccination. Arch. Virol. 2024;169:72. doi: 10.1007/s00705-024-05975-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-024-05975-y</ArticleId><ArticleId IdType="pubmed">38459213</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Nason M.C., Flach B., Gagne M., O’Connell S., Johnston T.S., Shah S.N., Edara V.V., Floyd K., Lai L., et al. Immune Correlates of Protection by mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Science. 2021;373:eabj0299. doi: 10.1126/science.abj0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj0299</ArticleId><ArticleId IdType="pmc">PMC8449013</ArticleId><ArticleId IdType="pubmed">34529476</ArticleId></ArticleIdList></Reference><Reference><Citation>Satti I., McShane H. Current Approaches toward Identifying a Correlate of Immune Protection from Tuberculosis. Expert Rev. Vaccines. 2019;18:43–59. doi: 10.1080/14760584.2019.1552140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1552140</ArticleId><ArticleId IdType="pubmed">30466332</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo J.C., Merin N.M., Hamid O., Choi S.Y., Lemos T., Cozen W., Nguyen N., Finster L.J., Foley J., Darrah J., et al. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Res. 2021;81:6273–6280. doi: 10.1158/0008-5472.CAN-21-3554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-3554</ArticleId><ArticleId IdType="pmc">PMC9060668</ArticleId><ArticleId IdType="pubmed">34759001</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry M.T., Khan S.R., Schlub T.E., Notaras A., Kunasekaran M., Grulich A.E., MacIntyre C.R., Davenport M.P., Khoury D.S. Predicting Vaccine Effectiveness for Mpox. Nat. Commun. 2024;15:3856. doi: 10.1038/s41467-024-48180-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48180-w</ArticleId><ArticleId IdType="pmc">PMC11078999</ArticleId><ArticleId IdType="pubmed">38719852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammershaimb E.A.D., Campbell J.D. Vaccine Development. Pediatr. Clin. N. Am. 2024;71:529–549. doi: 10.1016/j.pcl.2024.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcl.2024.01.018</ArticleId><ArticleId IdType="pubmed">38754940</ArticleId></ArticleIdList></Reference><Reference><Citation>Boraschi D., Li D., Li Y., Italiani P. In Vitro and In Vivo Models to Assess the Immune-Related Effects of Nanomaterials. Int. J. Environ. Res. Public Health. 2021;18:11769. doi: 10.3390/ijerph182211769.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182211769</ArticleId><ArticleId IdType="pmc">PMC8623312</ArticleId><ArticleId IdType="pubmed">34831525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch C., Schildknecht S. In Vitro Research Reproducibility: Keeping Up High Standards. Front. Pharmacol. 2019;10:1484. doi: 10.3389/fphar.2019.01484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01484</ArticleId><ArticleId IdType="pmc">PMC6916005</ArticleId><ArticleId IdType="pubmed">31920667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattes W.B. In Vitro to in Vivo Translation. Curr. Opin. Toxicol. 2020;23–24:114–118. doi: 10.1016/j.cotox.2020.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2020.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert-Vega C., Tawfik D.M., Trouillet-Assant S., Vachot L., Mallet F., Textoris J. Immune Functional Assays, From Custom to Standardized Tests for Precision Medicine. Front. Immunol. 2018;9:2367. doi: 10.3389/fimmu.2018.02367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02367</ArticleId><ArticleId IdType="pmc">PMC6198655</ArticleId><ArticleId IdType="pubmed">30386334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pondman K., Le Gac S., Kishore U. Nanoparticle-Induced Immune Response: Health Risk versus Treatment Opportunity? Immunobiology. 2023;228:152317. doi: 10.1016/j.imbio.2022.152317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2022.152317</ArticleId><ArticleId IdType="pubmed">36592542</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh D., Kim H.J., Fraser J.P., Shea D.E., Khan M., Bahinski A., Hamilton G.A., Ingber D.E. Microfabrication of Human Organs-on-Chips. Nat. Protoc. 2013;8:2135–2157. doi: 10.1038/nprot.2013.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.137</ArticleId><ArticleId IdType="pubmed">24113786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead B.E., Karp J.M. All Models Are Wrong, but Some Organoids May Be Useful. Genome Biol. 2019;20:66. doi: 10.1186/s13059-019-1677-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1677-4</ArticleId><ArticleId IdType="pmc">PMC6437983</ArticleId><ArticleId IdType="pubmed">30917855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang K.-J., Otieno M.A., Ronxhi J., Lim H.-K., Ewart L., Kodella K.R., Petropolis D.B., Kulkarni G., Rubins J.E., Conegliano D., et al. Reproducing Human and Cross-Species Drug Toxicities Using a Liver-Chip. Sci. Transl. Med. 2019;11:eaax5516. doi: 10.1126/scitranslmed.aax5516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax5516</ArticleId><ArticleId IdType="pubmed">31694927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroll K.T., Mata M.M., Homan K.A., Micallef V., Carpy A., Hiratsuka K., Morizane R., Moisan A., Gubler M., Walz A.-C., et al. Immune-Infiltrated Kidney Organoid-on-Chip Model for Assessing T Cell Bispecific Antibodies. Proc. Natl. Acad. Sci. USA. 2023;120:e2305322120. doi: 10.1073/pnas.2305322120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2305322120</ArticleId><ArticleId IdType="pmc">PMC10467620</ArticleId><ArticleId IdType="pubmed">37603766</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio E., Tondo G., Montabone C., Comi C. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature. Int. J. Environ. Res. Public Health. 2022;20:467. doi: 10.3390/ijerph20010467.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph20010467</ArticleId><ArticleId IdType="pmc">PMC9819717</ArticleId><ArticleId IdType="pubmed">36612789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lázaro Hernández C., Llauradó Gayete A., Sánchez-Tejerina San José D., Cabirta A., Carpio C., Sotoca J., Salvadó Figueras M., Raguer Sanz N., Restrepo J., Juntas Morales R. Síndrome de Guillain-Barré y trombocitopenia tras la vacunación contra el SARS-CoV-2 con Moderna. Descripción de un caso. Rev. Neurol. 2022;75:247. doi: 10.33588/rn.7508.2022138.</Citation><ArticleIdList><ArticleId IdType="doi">10.33588/rn.7508.2022138</ArticleId><ArticleId IdType="pmc">PMC10280725</ArticleId><ArticleId IdType="pubmed">36218255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J.T., Luján L., Blank M., Shoenfeld Y. Adjuvants- and Vaccines-Induced Autoimmunity: Animal Models. Immunol. Res. 2017;65:55–65. doi: 10.1007/s12026-016-8819-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8819-5</ArticleId><ArticleId IdType="pubmed">27417999</ArticleId></ArticleIdList></Reference><Reference><Citation>Seida I., Seida R., Elsalti A., Mahroum N. Vaccines and Autoimmunity—From Side Effects to ASIA Syndrome. Medicina. 2023;59:364. doi: 10.3390/medicina59020364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina59020364</ArticleId><ArticleId IdType="pmc">PMC9966463</ArticleId><ArticleId IdType="pubmed">36837564</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Liu X., Chen X., Li Q. Insights into New-Onset Autoimmune Diseases after COVID-19 Vaccination. Autoimmun. Rev. 2023;22:103340. doi: 10.1016/j.autrev.2023.103340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103340</ArticleId><ArticleId IdType="pmc">PMC10108562</ArticleId><ArticleId IdType="pubmed">37075917</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A., Tchen J., Ferré V.M., Nicaise-Roland P., Descamps D., Delory N., François C., Mendes C., Papo T., Goulenok T., et al. Impact of BNT162b2 mRNA Anti-SARS-CoV-2 Vaccine on Interferon-Alpha Production by Plasmacytoid Dendritic Cells and Autoreactive T Cells in Patients with Systemic Lupus Erythematosus: The COVALUS Project. J. Autoimmun. 2023;134:102987. doi: 10.1016/j.jaut.2022.102987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102987</ArticleId><ArticleId IdType="pmc">PMC9760608</ArticleId><ArticleId IdType="pubmed">36563528</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPiazza A.T., Graham B.S., Ruckwardt T.J. T Cell Immunity to SARS-CoV-2 Following Natural Infection and Vaccination. Biochem. Biophys. Res. Commun. 2021;538:211–217. doi: 10.1016/j.bbrc.2020.10.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.060</ArticleId><ArticleId IdType="pmc">PMC7584424</ArticleId><ArticleId IdType="pubmed">33190827</ArticleId></ArticleIdList></Reference><Reference><Citation>Conklin L., Hviid A., Orenstein W.A., Pollard A.J., Wharton M., Zuber P. Vaccine Safety Issues at the Turn of the 21st Century. BMJ Glob. Health. 2021;6:e004898. doi: 10.1136/bmjgh-2020-004898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2020-004898</ArticleId><ArticleId IdType="pmc">PMC8137241</ArticleId><ArticleId IdType="pubmed">34011504</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinou G.N. Explaining COVID-19 Postvaccination-Related Immune Thrombotic Thrombocytopenia: A Hypothesis-Generating in-Silico Approach. Hum. Vaccines Immunother. 2022;18:2050654. doi: 10.1080/21645515.2022.2050654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2050654</ArticleId><ArticleId IdType="pmc">PMC9196821</ArticleId><ArticleId IdType="pubmed">35412949</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022;185:881–895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xu Z., Wang P., Li X.-M., Shuai Z.-W., Ye D.-Q., Pan H.-F. New-Onset Autoimmune Phenomena Post-COVID-19 Vaccination. Immunology. 2022;165:386–401. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Loshaj-Shala A., Colzani M., Brezovska K., Poceva Panovska A., Suturkova L., Beretta G. Immunoproteomic Identification of Antigenic Candidate Campylobacter Jejuni and Human Peripheral Nerve Proteins Involved in Guillain-Barré Syndrome. J. Neuroimmunol. 2018;317:77–83. doi: 10.1016/j.jneuroim.2018.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2018.01.006</ArticleId><ArticleId IdType="pubmed">29338928</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang P., Zhu M., Wang Y., Zheng X., Wu X., Zhu J., Feng J., Zhang H.-L. Axonal Variants of Guillain–Barré Syndrome: An Update. J. Neurol. 2021;268:2402–2419. doi: 10.1007/s00415-020-09742-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09742-2</ArticleId><ArticleId IdType="pubmed">32140865</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Triggers of Guillain–Barré Syndrome: Campylobacter Jejuni Predominates. Int. J. Mol. Sci. 2022;23:14222. doi: 10.3390/ijms232214222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214222</ArticleId><ArticleId IdType="pmc">PMC9696744</ArticleId><ArticleId IdType="pubmed">36430700</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S., Malekpour M., Jabbari P., Rezaei N. Genetic Basis of Guillain-Barre Syndrome. J. Neuroimmunol. 2021;358:577651. doi: 10.1016/j.jneuroim.2021.577651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577651</ArticleId><ArticleId IdType="pubmed">34246981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kløve S., Genger C., Weschka D., Mousavi S., Bereswill S., Heimesaat M.M. Toll-Like Receptor-4 Is Involved in Mediating Intestinal and Extra-Intestinal Inflammation in Campylobacter Coli-Infected Secondary Abiotic IL-10-/- Mice. Microorganisms. 2020;8:1882. doi: 10.3390/microorganisms8121882.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8121882</ArticleId><ArticleId IdType="pmc">PMC7761268</ArticleId><ArticleId IdType="pubmed">33261211</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstappen G.M., De Wolff L., Arends S., Heiermann H.-M., Van Sleen Y., Visser A., Terpstra J.H., Diavatopoulos D.A., Van Der Heiden M., Vissink A., et al. Immunogenicity and Safety of COVID-19 Vaccination in Patients with Primary Sjögren’s Syndrome. RMD Open. 2022;8:e002265. doi: 10.1136/rmdopen-2022-002265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002265</ArticleId><ArticleId IdType="pmc">PMC9006196</ArticleId><ArticleId IdType="pubmed">35414631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>